1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,300 | 1,410 | 30.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.01. | LEO pharma gains EU rights to Junshi Biosciences' PD-1 inhibitor toripalimab | 1 | PMLiVE | ||
| 21.01. | Leo bags EU rights to Junshi's Loqtorzi, putting marketing muscle behind PD-1 launch | 1 | FiercePharma | ||
| 21.01. | Junshi partners LEO Pharma for toripalimab distribution in Europe | 1 | Pharmaceutical Technology | ||
| 20.01. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE DISTRIBUTION AND MARKETING AGREEMENT WITH LEO PHARMA | - | HKEx | ||
| 20.01. | Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe | 231 | GlobeNewswire (Europe) | SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.01. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE TGA FOR MARKETING OF TORIPALIMAB | - | HKEx | ||
| 17.01. | JUNSHI BIO (01877): INSIDE INFORMATION - 2024 RESULTS FORECAST | - | HKEx | ||
| 17.01. | Junshi Biosciences Announces Toripalimab's Approval in Australia | 309 | GlobeNewswire (Europe) | SHANGHAI, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 10.01. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - REGULAR APPROVAL OF DEUREMIDEVIR HYDROBROMIDE TABLETS BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | - | HKEx | ||
| 08.01. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JS212 INJECTION RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION | 1 | HKEx | ||
| 06.01. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - REGULAR APPROVAL OF TORIPALIMAB AS THE SECOND-LINE OR LATER TREATMENT OF MELANOMA BY THE NATIONAL MEDICAL ... | 1 | HKEx | ||
| 20.12.24 | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 20.12.24 | JUNSHI BIO (01877): ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE AND THE STRATEGIC COMMITTEE | - | HKEx | ||
| 20.12.24 | JUNSHI BIO (01877): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 20.12.24 | JUNSHI BIO (01877): POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.11.24 | JUNSHI BIO (01877): FORM OF PROXY FOR THE 2024 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, 20 DECEMBER 2024 | 2 | HKEx | ||
| 29.11.24 | JUNSHI BIO (01877): NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.11.24 | JUNSHI BIO (01877): (1) UTILIZATION OF REMAINING OVER-SUBSCRIPTION PROCEEDS FOR PERMANENT REPLENISHMENT OF LIQUIDITY (2) ELECTION OF INDEPENDENT NON-EXECUTIVE ... | 2 | HKEx | ||
| 29.11.24 | JUNSHI BIO (01877): PROPOSED ELECTION AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS | 3 | HKEx | ||
| 29.11.24 | JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 1 | HKEx |
Seite:
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,19 | 0,00 % | Tempus AI's Options Frenzy: What You Need to Know | ||
| EVOTEC | 8,580 | +5,66 % | Commerzbank, Deutsche Bank, Evotec, Infineon, Nvidia, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 54,73 | 0,00 % | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,670 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,690 | 0,00 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| BIONTECH | 116,60 | +0,34 % | BioNTech Aktie: Break über 131 Dollar könnte heftige Kursrallye auslösen | Die BioNTech Aktie legte gestern an der NASDAQ auf Schlusskursbasis mehr als sechs Prozent auf 122,12 Dollar zu und konnte ein kleines Kaufsignal generieren. Durch den Anstieg über das Gap bei 118,74/120... ► Artikel lesen | |
| MODERNA | 40,315 | -3,59 % | Moderna erhält den Zuschlag für die Belieferung der Europäischen Union mit seinem COVID-19-mRNA-Impfstoff | Die Vereinbarung bietet den teilnehmenden Ländern die Chance, ihre Versorgung mit dem COVID-19-mRNA-Impfstoff zu
diversifizieren und Zugang zu diesem Impfstoff in Form einer Fertigspritze zu... ► Artikel lesen | |
| CG ONCOLOGY | 30,150 | -0,30 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| CARGO THERAPEUTICS | 3,390 | 0,00 % | Safety Risk Sinks Cargo Therapeutics' Cancer Cell Therapy Prospect, Leading to 50% Staff Cut | ||
| 89BIO | 9,650 | +10,54 % | 89bio, Inc. - 8-K, Current Report | ||
| BB BIOTECH | 42,600 | +2,16 % | EQS-News: BB BIOTECH AG: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Jahresergebnis/Dividende
BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag
24.01.2025 / 07:00 CET/CEST
Für... ► Artikel lesen | |
| IMMUNOME | 10,510 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 10,290 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 22,320 | +3,14 % | Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? | ||
| AVIDITY BIOSCIENCES | 32,630 | +2,10 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.
